Therapeutic Effect of Sildenafil in Patients With Coronary Vasospasm

Status Withdrawn

Clinical Trial Summary

This will be a prospective, phase IIIb, double-blind and randomized trial testing the effect of single dose sildenafil application in patients with coronary vasospasm compared to placebo application.

The target variable to be tested is the degree of coronary vasoconstriction in response to intracoronary ACh application (in addition to clinical chest pain) which will be imaged by coronary angiography and measured using quantitative coronary angiography software.

Main objective: Has sildenafil the potency to inhibit the induction of coronary vasospasm by intracoronary ACh-application in patients with proven coronary artery spasm?

Secondary objective: Which degree of coronary vasospasm inhibition can be achieved with sildenafil?

Clinical Trial Description

Coronary artery spasm is an abrupt severe vasoconstrictor response which may occur spontaneously in normal and diseased coronary arteries. It may result in myocardial ischemia and may be provoked by various stimuli such as acetylcholine (ACh). Coronary vasospasm is involved in the pathogenesis of Prinzmetal's angina, acute myocardial infarction or sudden cardiac death due to ventricular arrythmias and chest pain symptoms associated with viral myocarditis.

The precise cellular and molecular mechanisms of coronary vasospasm have not yet been elucidated. The most often suggested but competing explanations for this disease are coronary endothelial dysfunction secondary to impaired nitric oxide production versus coronary smooth muscle cell hyperreactivity with or without additional endothelial dysfunction. As the precise cellular mechanism is currently unknown a large group of people can currently not be treated appropriately despite the use of nitrates and calcium antagonists.

Sildenafil is a phosphodiesterase(PDE)-5 inhibitor approved for the treatment of both erectile dysfunction and pulmonary hypertension. PDE-5 has been shown to be also present and play an important vasomotor role in the coronary vessel wall. Application of the inhibitor sildenafil has been shown to increase the resting coronary artery diameter. Furthermore, atherosclerotic coronary artery segments which vasoconstrict following intracoronary ACh-application vasodilate following the application of sildenafil when ACh-testing is repeated. Other studies are also suggesting an improved endothelial function after sildenafil application for both the coronary and the peripheral vasculature.

Taken together, sildenafil is expected to have a positive effect on coronary vasomotility. Whether sildenafil can totally prevent the occurrence of coronary vasospasm or at least decrease the severity of vasospasm has not been studied so far. Thus, the aim of this study is to analyse the possible anti-spastic effects of sildenafil in patients suffering from coronary vasospasm. ;

Study Design

Related Conditions & MeSH terms

Coronary Vasospasm

Clinical Trial Details

NCT number	NCT00454714
Study type	Interventional
Source	Robert Bosch Gesellschaft für Medizinische Forschung mbH
Contact
Status	Withdrawn
Phase	Phase 3
Start date	March 1, 2007
Completion date	December 31, 2009

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06125392` - Multicenter Registry on Microvascular Dysfunction - Searching a New Ach Spasm Definition
Recruiting	`NCT05288361` - The DISCOVER INOCA Prospective Multi-center Registry
Active, not recruiting	`NCT04777045` - Efficacy of Diltiazem to Improve Coronary Microvascular Dysfunction: a Randomized Clinical Trial	Phase 3
Enrolling by invitation	`NCT06083155` - The NetherLands Registry of Invasive Coronary Vasomotor Function Testing (NL-CFT)
Recruiting	`NCT04598308` - EUROpean Coronary microCirculatory Resistance and Absolute Flow Trial
Completed	`NCT03193294` - CORonary MICrovascular Angina (CorMicA)	N/A
Completed	`NCT02298543` - Coronary Spasm Presenting Aborted Sudden Cardiac Death, the Multicenter Registry	N/A
Recruiting	`NCT00921856` - Abnormal Coronary Vasomotion in Patients With Suspected Coronary Artery Disease (CAD)	N/A
Recruiting	`NCT05635994` - Advanced Invasive Diagnosis for Patients With Chronic Coronary Syndromes Undergoing Coronary ANGIOgraphy (AID-ANGIO)
Completed	`NCT03930433` - The Effect of Nebivolol in Hypertensive Patients With Coronary Arterial Spasm	Phase 4
Completed	`NCT00350129` - Effect of Glucose on Ocular Blood Flow
Completed	`NCT00619294` - Endothelial Dysfunction and Coronary Artery Spasm	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.